<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ccr371794" xml:lang="en" article-type="case-study" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Clin Case Rep</journal-id><journal-id journal-id-type="pmc-domain-id">2542</journal-id><journal-id journal-id-type="pmc-domain">ccr</journal-id><journal-id journal-id-type="publisher-id">CCR3</journal-id><journal-title-group><journal-title>Clinical Case Reports</journal-title></journal-title-group><issn pub-type="epub">2050-0904</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12772505</article-id><article-id pub-id-type="pmcid-ver">PMC12772505.1</article-id><article-id pub-id-type="pmcaid">12772505</article-id><article-id pub-id-type="pmcaiid">12772505</article-id><article-id pub-id-type="pmid">41503597</article-id><article-id pub-id-type="doi">10.1002/ccr3.71794</article-id><article-id pub-id-type="publisher-id">CCR371794</article-id><article-id pub-id-type="other">CCR3-2025-11-4409.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="article-subject-classification"><subject>Surgery</subject></subj-group><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Bilateral Breast Fibroadenoma With Bilateral Ductal Carcinoma In&#160;Situ: A Case Report</article-title></title-group><contrib-group><contrib id="ccr371794-cr-0001" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="S">Siyang</given-names></name><xref rid="ccr371794-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ccr371794-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xiaohua</given-names></name><xref rid="ccr371794-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>29780293@qq.com</email></address></contrib><contrib id="ccr371794-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Tian</surname><given-names initials="W">Wuguo</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6414-6808</contrib-id><xref rid="ccr371794-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>tianwuguogood@126.com</email></address></contrib></contrib-group><aff id="ccr371794-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Breast and Thyroid Surgery, Daping Hospital</named-content>
<institution>Army Military Medical University</institution>
<city>Chongqing</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Xiaohua Zhang (<email>29780293@qq.com</email>)<break/>
Wuguo Tian (<email>tianwuguogood@126.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>14</volume><issue seq="1430">1</issue><issue-id pub-id-type="pmc-issue-id">502911</issue-id><issue-id pub-id-type="doi">10.1002/ccr3.v14.1</issue-id><elocation-id>e71794</elocation-id><history><date date-type="rev-recd"><day>07</day><month>12</month><year>2025</year></date><date date-type="received"><day>13</day><month>11</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>07</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-08 09:25:13.073"><day>08</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2026 The Author(s). <italic toggle="yes">Clinical Case Reports</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CCR3-14-e71794.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CCR3-14-e71794.pdf"/><abstract><title>ABSTRACT</title><p>Breast fibroadenoma coexisting with ductal carcinoma in&#160;situ (DCIS) is clinically rare, with bilateral concurrent occurrence presenting greater diagnostic complexity. This report describes a young female patient who was initially diagnosed with bilateral breast fibroadenoma. Postoperative pathological examination revealed coexisting bilateral mammary fibroadenomas with DCIS. While mammary fibroadenomas are common benign lesions, their coexistence with DCIS often leads to missed diagnoses, potentially resulting in serious consequences. This case study highlights the importance of enhancing clinicians' understanding of breast lesion complexity and optimizing diagnostic and therapeutic protocols.</p></abstract><abstract abstract-type="highlights" id="CCR371794-abs-5001"><title>Key Clinical Message</title><p>
<list list-type="bullet" id="ccr371794-list-0001"><list-item id="ccr371794-li-0001"><p>Bilateral breast fibroadenomas coexisting with ductal carcinoma in&#160;situ in a young female are extremely rare.</p></list-item><list-item id="ccr371794-li-0002"><p>Treatment decisions are significant clinical challenges that should prioritize individualized care, balancing therapeutic efficacy with long&#8208;term quality of life.</p></list-item></list>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ccr371794-kwd-0001">bilateral</kwd><kwd id="ccr371794-kwd-0002">breast cancer</kwd><kwd id="ccr371794-kwd-0003">breast fibroadenoma</kwd><kwd id="ccr371794-kwd-0004">ductal carcinoma in&#160;situ</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Natural Science Foundation of Chongqing</institution><institution-id institution-id-type="doi">10.13039/501100011933</institution-id></institution-wrap></funding-source><award-id>CSTB2022NSCQ&#8208;MSX1228</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="4"/><word-count count="2000"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.6 mode:remove_FC converted:06.01.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ccr371794-cit-1001"><string-name name-style="western"><given-names>S.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Tian</surname></string-name>, &#8220;<article-title>Bilateral Breast Fibroadenoma With Bilateral Ductal Carcinoma In&#160;Situ: A Case Report</article-title>,&#8221; <source>Clinical Case Reports</source><volume>14</volume>, no. <issue>1</issue> (<year>2026</year>): <elocation-id>e71794</elocation-id>, <pub-id pub-id-type="doi">10.1002/ccr3.71794</pub-id>.</mixed-citation>
</p></notes></front><body id="ccr371794-body-0001"><sec id="ccr371794-sec-0001"><label>1</label><title>Introduction</title><p>Breast fibroadenoma is a common benign tumor in women, with an incidence rate of approximately 10% [<xref rid="ccr371794-bib-0001" ref-type="bibr">1</xref>]. However, cases involving ductal carcinoma in&#160;situ (DCIS) within the tumor are relatively rare, with reported incidence rates below 1% in the literature [<xref rid="ccr371794-bib-0002" ref-type="bibr">2</xref>]. DCIS refers to malignant proliferation of epithelial cells confined to the ducts, which has the potential to develop into invasive cancer [<xref rid="ccr371794-bib-0003" ref-type="bibr">3</xref>]. When DCIS occurs within a fibroadenoma, its benign clinical and imaging features often mask the malignant component, leading to diagnostic challenges before surgery. Currently, most reported cases worldwide are unilateral [<xref rid="ccr371794-bib-0004" ref-type="bibr">4</xref>, <xref rid="ccr371794-bib-0005" ref-type="bibr">5</xref>]. The mechanism of coexistence of DCIS and fibroadenoma is still unknown. It may be that the two are two independent tumors coexisting by chance. It may also be that the ductal epithelium in fibroadenoma undergoes malignant transformation under the action of long&#8208;term hormone stimulation or other factors. The occurrence of DCIS in both breast fibroadenomas seems to support the latter theory. This article presents a detailed case of DCIS identified within a bilateral breast fibroadenoma confirmed by pathology, exploring its clinical&#8208;pathological characteristics, diagnostic approaches, and treatment strategies to enhance clinicians' understanding and improve management of such rare case.</p></sec><sec id="ccr371794-sec-0002"><label>2</label><title>Case History/Examination</title><p>A 22&#8208;year&#8208;old unmarried woman without children, with no prior medical history or family history of breast cancer, was admitted for &#8220;discovery of bilateral breast masses over one month.&#8221; The patient had incidentally detected a mass in each upper outer quadrant of both breasts one month prior, without accompanying symptoms such as pain, nipple discharge, or skin changes. Clinical examination revealed symmetrical breasts with normal skin. Palpable masses were found in the upper outer quadrants: approximately 2.0&#8201;cm&#8201;&#215;&#8201;1.5&#8201;cm on the right and 2.5&#8201;cm&#8201;&#215;&#8201;2.0&#8201;cm on the left, with firm texture, well&#8208;defined borders, and good mobility. No enlarged lymph nodes were detected in the axillary region. Breast ultrasound showed hypoechoic nodules in the upper outer quadrants, with regular morphology, clear margins, and BI&#8208;RADS 3 classification.</p></sec><sec id="ccr371794-sec-0003"><label>3</label><title>Differential Diagnosis, Investigations and Treatment</title><p>Given imaging findings suggestive of grade 3 lesions, the patient underwent bilateral mastectomy after consultation. Gross specimens included: &lt;left breast tumor&gt;two grayish&#8208;yellow masses (approximately 2.8&#8201;&#215;&#8201;2.0&#8201;&#215;&#8201;0.5&#8201;cm in size); &lt;right breast tumor&gt;one grayish&#8208;yellow mass (approximately 3.0&#8201;&#215;&#8201;2.0&#8201;&#215;&#8201;1.8&#8201;cm). Pathological diagnosis confirmed fibroadenoma with ductal epithelial hyperplasia and cellular atypia in both tumors. Pathological confirmation of DCIS within breast fibroadenoma (Figure&#160;<xref rid="ccr371794-fig-0001" ref-type="fig">1</xref>). Immunohistochemical findings were: &lt;left&gt;: CK5/6 (scattered positive), ER (strongly positive, approximately 80%), PR (strongly positive, approximately 80%), Her&#8208;2 (+), Ki&#8208;67 (approximately 3%), P120 (membrane&#8208;positive), P63 (myoepithelial&#8208;positive); &lt;right&gt;: CK5/6 (scattered positive), ER (strongly positive, approximately 90%), PR (strongly positive, approximately 90%), Her&#8208;2 (+), Ki&#8208;67 (approximately 5%), P120 (membrane&#8208;positive), P63 (myoepithelial&#8208;positive) (Figure&#160;<xref rid="ccr371794-fig-0002" ref-type="fig">2</xref>). Due to uncertain margins and bilateral involvement, a second surgery was performed to expand the resection margins. Postoperative pathology revealed low&#8208;grade DCIS in both breasts with negative margins.</p><fig position="float" fig-type="FIGURE" id="ccr371794-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>HE staining (a) HE &#215;40&#8208;right breast typical fibroma area; (b) HE &#215;40&#8208;right breast fibroma area with partial cellular atypia; (c) HE &#215;100&#8208;right breast typical fibroma area showing DCIS; (d) HE &#215;40&#8208;left breast fibroma area; (e) HE &#215;40&#8208;left breast fibroma area with partial cellular atypia; (f) HE &#215;100&#8208;left breast typical fibroma area showing DCIS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CCR3-14-e71794-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="ccr371794-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Immunohistochemistry (a) &#215;100 right breast ER intracavitary tumor cells showed 90% strong positivity; (b) &#215;100 right breast PR intracavitary tumor cells showed 90% strong positivity; (c) &#215;100 right breast CK5/6 intracavitary tumor cells were negative; (d) &#215;100 right breast P63 perimysial epithelium was positive, intracavitary tumor cells were negative; (e) &#215;100 left breast ER intracavitary tumor cells showed 80% strong positivity; (f) &#215;100 left breast PR intracavitary tumor cells showed 80% strong positivity; (g) &#215;100 right breast CK5/6 intracavitary tumor cells were negative; (h) &#215;100 right breast P63 perimysial epithelium was positive, intracavitary tumor cells were negative.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CCR3-14-e71794-g002.jpg"/></fig></sec><sec id="ccr371794-sec-0004"><label>4</label><title>Outcome and Follow&#8208;Up</title><p>After thorough risk&#8211;benefit discussion, the patient agreed to tamoxifen endocrine therapy but declined radiotherapy. The patient recovered well and showed no signs of recurrence during 12&#8201;months of regular follow&#8208;up.</p></sec><sec sec-type="discussion" id="ccr371794-sec-0005"><label>5</label><title>Discussion</title><p>The clinical diagnosis is difficult and the imaging examination has some limitations. A 22&#8208;year&#8208;old woman presenting with bilateral breast masses is prone to initial clinical and imaging diagnoses of benign fibroadenoma. Complete surgical resection and definitive pathological diagnosis remain critical steps to avoid misdiagnosis. Even with core needle biopsy, the high risk of underdiagnosis persists due to potential localized DCIS lesions [<xref rid="ccr371794-bib-0006" ref-type="bibr">6</xref>, <xref rid="ccr371794-bib-0007" ref-type="bibr">7</xref>, <xref rid="ccr371794-bib-0008" ref-type="bibr">8</xref>]. Early differentiation between benign and malignant breast tumors, particularly the timely detection of malignant transformation in fibroadenomas, requires advanced diagnostic technologies to assist clinicians. Recent studies have demonstrated that optical methods can distinguish breast fibroadenomas from breast cancer, enabling early diagnosis and prognosis evaluation of breast cancer [<xref rid="ccr371794-bib-0009" ref-type="bibr">9</xref>, <xref rid="ccr371794-bib-0010" ref-type="bibr">10</xref>]. These methods provide a new way to diagnose breast fibroadenoma combined with DCIS.</p><p>Treatment decisions involve inherent contradictions and trade&#8208;offs. The core challenge in this case lies in balancing tumor eradication with maximizing preservation of physiological functions and ensuring long&#8208;term quality of life. While active surveillance is being evaluated as a potential new option for low&#8208;risk DCIS [<xref rid="ccr371794-bib-0009" ref-type="bibr">9</xref>], we recommend surgical resection with complete tumor removal and negative margins as the preferred approach for young patients. However, the high risk of breast cancer recurrence in carcinoma in&#160;situ, combined with the inherent high risk of local recurrence in younger patients, demands greater surgical precision and wider margins [<xref rid="ccr371794-bib-0010" ref-type="bibr">10</xref>]. Adjuvant radiotherapy presents the most contentious aspect of treatment decision&#8208;making. Although it significantly reduces local recurrence risks after breast&#8208;conserving surgery for DCIS, it may cause long&#8208;term effects on breast tissue in young patients, including fibrosis, potential impacts on future breastfeeding, and the rare risk of secondary malignancy. The decision to administer radiotherapy to both breasts requires thorough multidisciplinary team (MDT) discussions with patients and their families to carefully weigh pros and cons. According to DCIS treatment guidelines, tamoxifen remains the standard endocrine therapy for hormone receptor&#8208;positive DCIS [<xref rid="ccr371794-bib-0011" ref-type="bibr">11</xref>]. For a 22&#8208;year&#8208;old patient, comprehensive consideration must be given to potential impacts on menstrual cycles, thrombotic risks, and future fertility plans. When necessary, collaboration with reproductive medicine specialists should be pursued to explore fertility preservation options before initiating endocrine therapy. The bilateral involvement in this case strongly suggests systemic hormonal abnormalities, suggesting potentially greater necessity for endocrine therapy, though the decision&#8208;making process must remain exceptionally cautious.</p><p>Genetic susceptibility should be considered in case of bilateral fibroadenomas with DCIS. While previous studies predominantly documented DCIS within unilateral fibromas [<xref rid="ccr371794-bib-0004" ref-type="bibr">4</xref>, <xref rid="ccr371794-bib-0005" ref-type="bibr">5</xref>], this report presents a bilateral fibroma coexisting with DCIS. Despite the absence of genetic testing in this case, we still recommend germ cell gene testing, such as BRCA1/2, is crucial not only for assessing the patient's risk and long&#8208;term management of the contralateral breast and ovaries, but also provides significant guidance for health screening of their immediate family members [<xref rid="ccr371794-bib-0012" ref-type="bibr">12</xref>]. These test results may directly influence decisions regarding preventive surgery.</p><p>This case of a 22&#8208;year&#8208;old female with bilateral breast fibroadenomas and bilateral DCIS presents a significant clinical challenge. Although malignant tumors are rare in young patients, they must be diagnosed with precision medicine while eliminating age&#8208;related biases. Treatment decisions should prioritize individualized care, balancing therapeutic efficacy with long&#8208;term quality of life. Genetic testing and comprehensive life&#8208;cycle health management form the foundation for ensuring long&#8208;term prognosis in breast cancer patients. This case provides valuable insights and profound lessons for managing similarly complex young&#8208;onset breast diseases.</p></sec><sec id="ccr371794-sec-0013"><title>Author Contributions</title><p>
<bold>Siyang Wang:</bold> data curation, visualization, writing &#8211; original draft, writing &#8211; review and editing. <bold>Xiaohua Zhang:</bold> data curation, formal analysis, writing &#8211; original draft, writing &#8211; review and editing. <bold>Wuguo Tian:</bold> writing &#8211; original draft, writing &#8211; review and editing.</p></sec><sec id="ccr371794-sec-0007"><title>Funding</title><p>This study was supported by the Natural Science Foundation of Chongqing (CSTB2022NSCQ&#8208;MSX1228).</p></sec><sec id="ccr371794-sec-0008"><title>Ethics Statement</title><p>This article is about a case study. As a result, our Ethics Committee's consent was not required.</p></sec><sec sec-type="conclusions" id="ccr371794-sec-0009"><title>Consent</title><p>Written informed consent was obtained from the patient for publication of this case report and accompanying images.</p></sec><sec sec-type="COI-statement" id="ccr371794-sec-0010"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="ccr371794-sec-0006"><title>Acknowledgments</title><p>The authors have nothing to report.</p></ack><sec sec-type="data-availability" id="ccr371794-sec-0012"><title>Data Availability Statement</title><p>All relevant data is within the manuscript.</p></sec><ref-list content-type="cited-references" id="ccr371794-bibl-0001"><title>References</title><ref id="ccr371794-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ccr371794-cit-0001"><string-name name-style="western"><given-names>N. J.</given-names><surname>Carty</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Carter</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Rubin</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Ravichandran</surname></string-name>, <string-name name-style="western"><given-names>G. T.</given-names><surname>Royle</surname></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Taylor</surname></string-name>, &#8220;<article-title>Management of Fibroadenoma of the Breast</article-title>,&#8221; <source>Annals of the Royal College of Surgeons of England</source><volume>77</volume> (<year>1995</year>): <fpage>127</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">7793802</pub-id><pub-id pub-id-type="pmcid">PMC2502143</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ccr371794-cit-0002"><string-name name-style="western"><given-names>M.</given-names><surname>Fukuda</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Nagao</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Nishimura</surname></string-name>, et&#160;al., &#8220;<article-title>Carcinoma Arising in Fibroadenoma of the Breast&#8211;A Case Report and Review of the Literature</article-title>,&#8221; <source>Japanese Journal of Surgery</source><volume>19</volume>, no. <issue>5</issue> (<year>1989</year>): <fpage>593</fpage>&#8211;<lpage>596</lpage>.<pub-id pub-id-type="pmid">2593394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02471669</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ccr371794-cit-0003"><string-name name-style="western"><given-names>T. S.</given-names><surname>Hulahan</surname></string-name> and <string-name name-style="western"><given-names>P. M.</given-names><surname>Angel</surname></string-name>, &#8220;<article-title>From Ductal Carcinoma In&#160;Situ to Invasive Breast Cancer: The Prognostic Value of the Extracellular Microenvironment</article-title>,&#8221; <source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>43</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>329</fpage>.<pub-id pub-id-type="pmid">39716322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-024-03236-z</pub-id><pub-id pub-id-type="pmcid">PMC11664872</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ccr371794-cit-0004"><string-name name-style="western"><given-names>J.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>K. W.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>Q. P.</given-names><surname>Mo</surname></string-name>, <string-name name-style="western"><given-names>Z. R.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>M. C.</given-names><surname>Zhong</surname></string-name>, &#8220;<article-title>Preoperational Diagnosis and Management of Breast Ductal Carcinoma In&#160;Situ Arising Within Fibroadenoma: Two Case Reports</article-title>,&#8221; <source>World Journal of Clinical Cases</source><volume>10</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>3496</fpage>&#8211;<lpage>3504</lpage>.<pub-id pub-id-type="pmid">35611194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12998/wjcc.v10.i11.3496</pub-id><pub-id pub-id-type="pmcid">PMC9048540</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ccr371794-cit-0005"><string-name name-style="western"><given-names>X. H.</given-names><surname>Ni</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>An</surname></string-name>, <string-name name-style="western"><given-names>Q. W.</given-names><surname>Shi</surname></string-name>, et&#160;al., &#8220;<article-title>Low&#8208;Grade Ductal Carcinoma In&#160;Situ Within a Fibroadenoma of the Breast: A Rare Case Report and Review of the Literature</article-title>,&#8221; <source>OncoTargets and Therapy</source><volume>16</volume> (<year>2023</year>): <fpage>399</fpage>&#8211;<lpage>406</lpage>.<pub-id pub-id-type="pmid">37325202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/OTT.S413223</pub-id><pub-id pub-id-type="pmcid">PMC10263016</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ccr371794-cit-0006"><string-name name-style="western"><given-names>P.</given-names><surname>Caswell&#8208;Smith</surname></string-name> and <string-name name-style="western"><given-names>M.</given-names><surname>Wall</surname></string-name>, &#8220;<article-title>Ductal Carcinoma In&#160;Situ: Is Core Needle Biopsy Ever Enough?</article-title>,&#8221; <source>Journal of Medical Imaging and Radiation Oncology</source><volume>61</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>29</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="pmid">27554420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1754-9485.12503</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ccr371794-cit-0007"><string-name name-style="western"><given-names>M.</given-names><surname>Akhtar</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Siddique</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Majid</surname></string-name>, et&#160;al., &#8220;<article-title>Ex&#8208;Vivo Optical Prognosis of Fibroadenoma and Grade II &amp; III Breast Cancer</article-title>,&#8221; <source>Lasers in Medical Science</source><volume>40</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>122</fpage>.<pub-id pub-id-type="pmid">40024932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10103-025-04285-2</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ccr371794-cit-0008"><string-name name-style="western"><given-names>M.</given-names><surname>Akhtar</surname></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Karar</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Siddique</surname></string-name>, et&#160;al., &#8220;<article-title>Harnessing Optics and Statistics for Early Detection and Prognosis in Breast and Ovarian Cancer</article-title>,&#8221; <source>Lasers in Medical Science</source><volume>40</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>279</fpage>.<pub-id pub-id-type="pmid">40515796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10103-025-04528-2</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ccr371794-cit-0009"><string-name name-style="western"><given-names>S.</given-names><surname>Delaloge</surname></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Khan</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wesseling</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Whelan</surname></string-name>, &#8220;<article-title>Ductal Carcinoma In&#160;Situ of the Breast: Finding the Balance Between Overtreatment and Undertreatment</article-title>,&#8221; <source>Lancet</source><volume>403</volume>, no. <issue>10445</issue> (<year>2024</year>): <fpage>2734</fpage>&#8211;<lpage>2746</lpage>.<pub-id pub-id-type="pmid">38735296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)00425-2</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ccr371794-cit-0010"><string-name name-style="western"><given-names>J.</given-names><surname>Zhou</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Lin</surname></string-name>, et&#160;al., &#8220;<article-title>Identification of High&#8208; and Low&#8208;Risk Groups for Ipsilateral Recurrence Within 10&#8201;Years After Breast&#8208;Conserving Surgery for Ductal Carcinoma In&#160;Situ and Personalized Treatment: A Retrospective Study</article-title>,&#8221; <source>Gland Surgery</source><volume>14</volume>, no. <issue>7</issue> (<year>2025</year>): <fpage>1213</fpage>&#8211;<lpage>1229</lpage>.<pub-id pub-id-type="pmid">40771374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/gs-2025-100</pub-id><pub-id pub-id-type="pmcid">PMC12322759</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ccr371794-cit-0011"><string-name name-style="western"><given-names>E. S.</given-names><surname>Hwang</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Hyslop</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Lynch</surname></string-name>, et&#160;al., &#8220;<article-title>Active Monitoring With or Without Endocrine Therapy for Low&#8208;Risk Ductal Carcinoma In&#160;Situ: The COMET Randomized Clinical Trial</article-title>,&#8221; <source>Journal of the American Medical Association</source><volume>333</volume>, no. <issue>11</issue> (<year>2025</year>): <fpage>972</fpage>&#8211;<lpage>980</lpage>.<pub-id pub-id-type="pmid">39665585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2024.26698</pub-id><pub-id pub-id-type="pmcid">PMC11920841</pub-id></mixed-citation></ref><ref id="ccr371794-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ccr371794-cit-0012"><string-name name-style="western"><given-names>P.</given-names><surname>Pourmasoumi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Moradi</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Bayat</surname></string-name>, &#8220;<article-title>BRCA1/2 Mutations and Breast/Ovarian Cancer Risk: A New Insights Review</article-title>,&#8221; <source>Reproductive Sciences</source><volume>31</volume>, no. <issue>12</issue> (<year>2024</year>): <fpage>3624</fpage>&#8211;<lpage>3634</lpage>.<pub-id pub-id-type="pmid">39107554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s43032-024-01666-w</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>